Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Bought by Fmr LLC

Fmr LLC grew its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 18.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 210,312 shares of the biopharmaceutical company’s stock after purchasing an additional 32,789 shares during the period. Fmr LLC owned approximately 0.38% of Cara Therapeutics worth $65,000 at the end of the most recent reporting period.

Separately, Disciplined Growth Investors Inc. MN lifted its holdings in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the period. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Stock Up 1.4 %

Shares of Cara Therapeutics stock opened at $0.46 on Wednesday. The business has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.32. Cara Therapeutics, Inc. has a fifty-two week low of $0.23 and a fifty-two week high of $1.15. The firm has a market cap of $25.43 million, a price-to-earnings ratio of -0.26 and a beta of 0.64.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a research note on Monday. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $2.32.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.